Scarica l'app Stockscreener
11.23
2.00%
0.22
Dopo l'orario di chiusura:
11.34
0.11
+0.98%
Design Therapeutics Inc Borsa (DSGN) Ultime notizie
Panic Selling: What is the long term forecast for Design Therapeutics Inc stockMarket Risk Report & Community Verified Trade Alerts - baoquankhu1.vn
Stock List: Research Stocks from Around the World - GuruFocus
DSGN.O PE Ratio & Valuation, Is DSGN.O Overvalued - intellectia.ai
DSGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oppenheimer initiates coverage of Design Therapeutics (DSGN) with outperform recommendation - msn.com
Design Therapeutics (NASDAQ:DSGN) Reaches New 12-Month HighHere's What Happened - marketbeat.com
Director David Shapiro granted 67,500 DSGN stock options (DSGN) - Stock Titan
Design Therapeutics (DSGN) director David Shapiro submits Form 3 - Stock Titan
Design Therapeutics, Inc. Appoints David Shapiro, M.D. as Class III Director and as Nominating and Corporate Governance Committee Member, Effective March 31, 2026 - MarketScreener
David Shapiro joins Design Therapeutics (DSGN) board with equity awards - Stock Titan
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Value Recap: Can Design Therapeutics Inc expand its profit marginsEarnings Miss & Capital Efficient Trading Techniques - baoquankhu1.vn
Asha Therapeutics Launches as First Atom Therapeutics, a Zero-Shot De Novo Drug Design Company - businesswire.com
DSGN.O Stock News Today | Earnings, Events & Price Alerts - intellectia.ai
Design Therapeutics (DSGN) price target increased by 12.82% to 14.96 - msn.com
Fuchs Dystrophy Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Kowa Pharma, Trefoil Therapeutics, Design Therapeutics, Emmecell, Santen - barchart.com
Fed Meeting: Will Design Therapeutics Inc benefit from current market trendsDip Buying & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
DSGN Earnings History & Surprises | EPS & Revenue Results | DESIGN THERAPEUTICS INC (NASDAQ:DSGN) - ChartMill
Absci Reports Positive ABS-201 Clinical Progress, Strong Financials, and Advances AI-Designed Therapeutics Pipeline in 2025 Results - Minichart
DSGN Technical Analysis & Stock Price Forecast - Intellectia AI
Aug EndMonth: Will Design Therapeutics Inc benefit from green energy policies2026 Buyback Activity & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Dyno Therapeutics Launches Dyno Psi-Phi, an Agentic AI Suite for Protein Binder Design, at NVIDIA GTC 2026 - Business Wire
Basecamp Research Launches Trillion Gene Atlas to Scale AI-Designed Therapeutics - The Manila Times
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma - Barchart.com
Design Therapeutics (NASDAQ:DSGN) Sets New 1-Year HighHere's Why - MarketBeat
Design Therapeutics (DSGN) Receives a New Rating from a Top Analyst - The Globe and Mail
Design Therapeutics (NASDAQ:DSGN) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Jefferies Initiates Coverage On Design Therap... - Benzinga
Design Therapeutics (NASDAQ:DSGN) Now Covered by Jefferies Financial Group - MarketBeat
Jefferies Initiates Coverage on Design Therapeutics With Buy Rating, $15 Price Target - marketscreener.com
Jefferies initiates Design Therapeutics stock with buy on drug potential - Investing.com
Jefferies initiates Design Therapeutics stock with buy on drug potential By Investing.com - Investing.com Australia
Design Therapeutics Maps H2 Data Readouts for RESTORE-FA, FECD Biomarker Study and DM1 Program - Yahoo Finance
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% on Analyst Upgrade - Defense World
Design Therapeutics Inc devrait afficher une perte de 33 cents par actionEarnings AVANT-PAPIER - TradingView
[SCHEDULE 13D/A] Design Therapeutics, Inc. Amended Major Shareholder Report - Stock Titan
Aug Breakouts: Can Design Therapeutics Inc expand its profit margins2026 Spike Watch & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Design Therapeutics (NASDAQ:DSGN) Stock Price Up 6.7% After Analyst Upgrade - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Design Therapeutics (DSGN) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC) - The Globe and Mail
Piper Sandler reiterates Overweight on Design Therapeutics stock By Investing.com - Investing.com South Africa
RBC Capital raises Design Therapeutics stock price target on programs By Investing.com - Investing.com Australia
Design Therapeutics, Inc. 2025 Annual Report: GeneTAC® Platform, Genomic Medicine Strategy, and Pipeline Overview - Minichart
Royal Bank Of Canada Forecasts Strong Price Appreciation for Design Therapeutics (NASDAQ:DSGN) Stock - MarketBeat
RBC Capital raises Design Therapeutics stock price target on programs - Investing.com
Piper Sandler reiterates Overweight on Design Therapeutics stock - Investing.com
Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates - The Manila Times
Design Therapeutics (NASDAQ:DSGN) Announces Earnings Results - MarketBeat
Design Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
DSGN: GeneTACⓇ platform advances four programs for genetic diseases, with strong clinical and financial momentum - TradingView
Design Therapeutics Provides Update on Clinical Trials and Financial Position for 2025 - Quiver Quantitative
Design Therapeutics reports lower-than-expected Q4 net loss - TradingView
DSGN: Net loss rose to $69.8M in 2025 as R&D spending increased; $219.8M cash at year-end - TradingView
Design Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
GeneTAC pipeline advances at Design Therapeutics (NASDAQ: DSGN) in FA, FECD, DM1 and HD - Stock Titan
DSGN: Clinical pipeline advanced, net loss $69.8M, cash reserves $219.8M fund operations into 2029 - TradingView
Design Therapeutics (Nasdaq: DSGN) widens 2025 loss but keeps $219.8M cash - Stock Titan
Three genetic disease trials push ahead at Design Therapeutics - Stock Titan
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):